Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Quest Diagnostics Incorporated (NYSE:DGX) is expected to release earnings results for its fourth quarter, before the opening bell on Feb. 1, 2024.
Analysts expect the company to report quarterly earnings at $2.11 per share, up from year-ago earnings of $1.98 per share. The company is projected to report revenue of $2.25 billion, compared to $2.33 billion in the year-earlier quarter, according to data from Benzinga Pro.
Fitbit and Quest Diagnostics announced a collaboration to advance research on the use of wearable devices to improve metabolic health.
Quest Diagnostics shares fell 0.3% to close at $128.43 on Wednesday.
Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.
Read This Next: $16.5M Bet On This Healthcare Stock? Check Out These 4 Stocks Insiders Are Buying
Posted In: DGX